
Amgen's PCSK9 mAb Shown to Protect Against Heart Attack and Stroke
According to results from the FOURIER trial, Repatha significantly reduced the risk of cardiovascular events and death in patients with atherosclerotic cardiovascular disease.
Amgen announced on Feb. 2, 2017 that the company’s FOURIER trial met its endpoints and that treatment with Repatha successfully reduced the risk of heart attack and stroke in patients whose low density lipoprotein cholesterol (LDL or LDL-C) was inadequately controlled with statins. Detailed results from the Repatha FOURIER outcomes trial and the related EBBINGHAUS trial will be presented at the American College of Cardiology meeting on March 17–18, 2017.
In the prior OSLER-1 and OSLER-2 trials for Repatha, there was evidence of an increase in adverse neurocognitive events. Approximately 1900 patients enrolled in the new FOURIER study were also enrolled in the EBBINGHAUS study-which measured memory and psychomotor speed-to assess the overall neurocognitive function of patients who were treated with Repatha.
Amgen banking on broader access and improved uptake
This new, protective indication could serve to make Repatha more attractive to payers in the long run and could allow the product to enjoy broader access. Currently, 75% of Repatha prescriptions
The new efficacy data, coupled with a monopoly position in the market due to a
In light of the aforementioned circumstances, it appears that a
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.